Upstream Bio (NASDAQ:UPB) Reaches New 52-Week Low - Should You Sell?

Shares of Upstream Bio, Inc. (NASDAQ:UPB - Get Free Report) reached a new 52-week low on Wednesday . The stock traded as low as $17.04 and last traded at $17.04, with a volume of 219283 shares trading hands. The stock had previously closed at $19.63.

Analysts Set New Price Targets

A number of research firms have commented on UPB. William Blair assumed coverage on shares of Upstream Bio in a research note on Tuesday, November 5th. They issued an "outperform" rating on the stock. TD Cowen started coverage on Upstream Bio in a research note on Tuesday, November 5th. They set a "buy" rating for the company. Piper Sandler started coverage on Upstream Bio in a research report on Tuesday, November 5th. They set an "overweight" rating and a $75.00 price objective for the company. Finally, JPMorgan Chase & Co. assumed coverage on Upstream Bio in a report on Tuesday, November 5th. They issued an "overweight" rating and a $38.00 target price on the stock.

Upstream Bio Stock Down 17.9 %

The firm has a fifty day moving average of $23.22.

Upstream Bio (NASDAQ:UPB - Get Free Report) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($6.96) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.58) by ($6.38). The business had revenue of $0.61 million for the quarter, compared to the consensus estimate of $0.83 million. Research analysts forecast that Upstream Bio, Inc. will post -4.3 earnings per share for the current year.

Insider Buying and Selling at Upstream Bio

In other Upstream Bio news, Director Erez Chimovits purchased 825,000 shares of the stock in a transaction on Tuesday, October 15th. The stock was bought at an average price of $17.00 per share, for a total transaction of $14,025,000.00. Following the acquisition, the director now directly owns 4,554,873 shares of the company's stock, valued at $77,432,841. This represents a 22.12 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at this link. Also, major shareholder Ai Upstream Llc acquired 1,175,000 shares of the company's stock in a transaction dated Tuesday, October 15th. The shares were bought at an average cost of $17.00 per share, with a total value of $19,975,000.00. Following the purchase, the insider now owns 1,175,000 shares in the company, valued at approximately $19,975,000. The trade was a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here.

Upstream Bio Company Profile

Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.